FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003013893> ?p ?o ?g. }

• W2003013893 endingPage "696" @default.
• W2003013893 startingPage "694" @default.
• W2003013893 abstract "To the Editor:Cystic fibrosis (CF) is a lethal autosomal recessive inherited disease caused by the loss or dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride (Cl−) channel activity resulting from mutations (1, 2). More than 1,600 mutations, which can be broadly grouped into six classes, have been identified in the CFTR gene (3). The incidence of CF and the frequency of specific mutations have been found to vary among ethnic populations (4, 5).We presented a clinical case of a young Hispanic patient with CF heterozygous for c.1521_1523delCTT (p.Phe508del or F508del)/c.1646G>A (p.Ser549Asn or S549N) mutations (please note that the legacy names for the mutations will be used in this letter). This individual was diagnosed with CF at 5 months of age after multiple hospitalizations due to dehydration, failure to thrive, and emesis. She also had a prolonged and persistent cough thought secondary to a diagnosis of pertussis at 4 months of age. At diagnosis, she was also noted to have a hypochloremic, hypokalemic metabolic alkalosis. She was below the fifth percentile on all aspects of her growth curve. Sweat chloride levels were abnormal with values of 87.1 mmol/L (right arm) and 78.2 mmol/L (left arm). She was empirically given pancreatic replacement enzymes and fat soluble vitamin replacement. By the age of 3 years, she was found to be colonized by two strains of nonmucoid Pseudomonas aeruginosa as well as a mucoid Pseudomonas that was her predominant isolate by 4 years of age. Over the past 2 years, she has had three additional hospitalizations for pulmonary exacerbations (April 2010, April 2011, and October 2011). Pulmonary function tests (PFTs) have continued to worsen with FEV1 values of 50 to 60% predicted (the most recent FEV1 prior to hospitalization in October 2011 was 51% predicted) and FEF25–75 values in the low end of 20 to 40% predicted (the most recent value was 20% predicted). She has had increasing pulmonary symptoms and has developed worsening sinusitis. Chest computed tomography scan completed in October 2011 showed areas of extensive bronchiectasis and fibrotic change, predominantly affecting the upper lobes. Areas of disease were observed in the lower lobes as well (Figure 1A and Figure E1 in the online supplement). There are numerous areas of “tree-in-bud” opacities present essentially involving all lobes of both lungs (Figure 1A).Figure 1.S549-CFTR is a regulation mutant and associates with a severe cystic fibrosis (CF) lung disease in a young Hispanic patient with CF. (A) Chest computed tomography (coronal view) shows extensive bilateral upper lobe bronchiectasis (arrows, left > ...F508del is the most common CFTR mutation, with more than 90% of patients with CF carrying it on at least one allele. F508del-CFTR protein is insufficiently folded and is trapped in the endoplasmic reticulum and targeted for degradation (1). Like c.1652G>A (p.Gly551Asp or G551D), S549N mutation occurs in the signature sequence (LSGGQ) of the first nucleotide-binding domain on the CFTR protein (Figure E2A). S549N mutation was first reported by Curtis and colleagues in a Pakistani individual who was homozygous for S549N and demonstrated severe malnutrition, growth retardation, and advanced pulmonary disease (6). S549N mutation was found to be prevalent among Hispanic, African American, and Asian populations (4).We characterized S549N-CFTR at the protein level to understand its molecular characteristics and the associated severe disease phenotype and, more importantly, to explore using mutation-specific therapy for medical interventions. S549N-CFTR was expressed as a mature form of CFTR (band C) with levels comparable to wild-type CFTR (Figure 1B). Surface labeling assay and fluorescence microscopy data showed that S549N-CFTR was expressed at the plasma membrane of cells (Figures E3A and E3B). However, S549N-CFTR lacks Cl− channel function (Figures E2B and E2C). These molecular characteristics correlate well with the severe CF phenotype we observed and suggest that, like G551D, S549N-CFTR is probably a regulation mutant.Ivacaftor (VX-770) is a CFTR potentiator that can restore the defective gating of G551D and several other regulation mutants (7–9) and has been approved by U.S. Food and Drug Administration for treating patients with CF aged 6 and older with G551D mutation (10). We expressed S549N-CFTR in polarized human cystic fibrosis bronchial epithelial cells (CFBEo−) and tested the effect of ivacaftor on CFTR channel function. Our results showed that ivacaftor restored the defective channel function of S549N-CFTR (Figure 1C), suggesting that ivacaftor has potential clinical benefit for patients with CF with S549N mutation. Our biochemical findings are consistent with data from a recent study in which ivacaftor was found to potentiate the channel open probability and total Cl− transport of S549N-CFTR expressed in Fischer rat thyroid cells (9). To further confirm S549N is a regulation mutant and can be rescued by CFTR potentiators, we also tested the effect of another known CFTR potentiator, P1, on the channel function of S549N-CFTR expressed in CFBEo− cells or human embryonic kidney (HEK-293) cells and found that P1 exerted a potentiating effect similar to that of ivacaftor (Figures E4 and E5).Because this subject in our study is heterozygous for F508del/S549N mutations, she would be an ideal candidate for the ongoing combinational trials using VX-809 (11) and ivacaftor and, most likely, will benefit from these trials." @default.
• W2003013893 created "2016-06-24" @default.
• W2003013893 creator A5020815278 @default.
• W2003013893 creator A5024897384 @default.
• W2003013893 creator A5045543880 @default.
• W2003013893 creator A5045938099 @default.
• W2003013893 creator A5048231866 @default.
• W2003013893 creator A5057153782 @default.
• W2003013893 creator A5059159168 @default.
• W2003013893 creator A5069690311 @default.
• W2003013893 creator A5073951705 @default.
• W2003013893 creator A5075828988 @default.
• W2003013893 creator A5078684676 @default.
• W2003013893 date "2012-10-01" @default.
• W2003013893 modified "2023-10-12" @default.
• W2003013893 title "A Young Hispanic with c.1646G>A Mutation Exhibits Severe Cystic Fibrosis Lung Disease: Is Ivacaftor an Option for Therapy?" @default.
• W2003013893 cites W1967050041 @default.
• W2003013893 cites W1975971473 @default.
• W2003013893 cites W1976197028 @default.
• W2003013893 cites W1983201355 @default.
• W2003013893 cites W2035131077 @default.
• W2003013893 cites W2052588826 @default.
• W2003013893 cites W2071407356 @default.
• W2003013893 cites W2085369501 @default.
• W2003013893 cites W2090878878 @default.
• W2003013893 cites W2093935222 @default.
• W2003013893 cites W2140868856 @default.
• W2003013893 doi "https://doi.org/10.1164/ajrccm.186.7.694" @default.
• W2003013893 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3480516" @default.
• W2003013893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23027855" @default.
• W2003013893 hasPublicationYear "2012" @default.
• W2003013893 type Work @default.
• W2003013893 sameAs 2003013893 @default.
• W2003013893 citedByCount "8" @default.
• W2003013893 countsByYear W20030138932013 @default.
• W2003013893 countsByYear W20030138932014 @default.
• W2003013893 countsByYear W20030138932015 @default.
• W2003013893 countsByYear W20030138932016 @default.
• W2003013893 countsByYear W20030138932018 @default.
• W2003013893 countsByYear W20030138932022 @default.
• W2003013893 crossrefType "journal-article" @default.
• W2003013893 hasAuthorship W2003013893A5020815278 @default.
• W2003013893 hasAuthorship W2003013893A5024897384 @default.
• W2003013893 hasAuthorship W2003013893A5045543880 @default.
• W2003013893 hasAuthorship W2003013893A5045938099 @default.
• W2003013893 hasAuthorship W2003013893A5048231866 @default.
• W2003013893 hasAuthorship W2003013893A5057153782 @default.
• W2003013893 hasAuthorship W2003013893A5059159168 @default.
• W2003013893 hasAuthorship W2003013893A5069690311 @default.
• W2003013893 hasAuthorship W2003013893A5073951705 @default.
• W2003013893 hasAuthorship W2003013893A5075828988 @default.
• W2003013893 hasAuthorship W2003013893A5078684676 @default.
• W2003013893 hasBestOaLocation W20030138932 @default.
• W2003013893 hasConcept C104317684 @default.
• W2003013893 hasConcept C126322002 @default.
• W2003013893 hasConcept C177713679 @default.
• W2003013893 hasConcept C2776502428 @default.
• W2003013893 hasConcept C2776938444 @default.
• W2003013893 hasConcept C2777714996 @default.
• W2003013893 hasConcept C2778428886 @default.
• W2003013893 hasConcept C2779134260 @default.
• W2003013893 hasConcept C2983914783 @default.
• W2003013893 hasConcept C501734568 @default.
• W2003013893 hasConcept C54355233 @default.
• W2003013893 hasConcept C71924100 @default.
• W2003013893 hasConcept C86803240 @default.
• W2003013893 hasConceptScore W2003013893C104317684 @default.
• W2003013893 hasConceptScore W2003013893C126322002 @default.
• W2003013893 hasConceptScore W2003013893C177713679 @default.
• W2003013893 hasConceptScore W2003013893C2776502428 @default.
• W2003013893 hasConceptScore W2003013893C2776938444 @default.
• W2003013893 hasConceptScore W2003013893C2777714996 @default.
• W2003013893 hasConceptScore W2003013893C2778428886 @default.
• W2003013893 hasConceptScore W2003013893C2779134260 @default.
• W2003013893 hasConceptScore W2003013893C2983914783 @default.
• W2003013893 hasConceptScore W2003013893C501734568 @default.
• W2003013893 hasConceptScore W2003013893C54355233 @default.
• W2003013893 hasConceptScore W2003013893C71924100 @default.
• W2003013893 hasConceptScore W2003013893C86803240 @default.
• W2003013893 hasIssue "7" @default.
• W2003013893 hasLocation W20030138931 @default.
• W2003013893 hasLocation W20030138932 @default.
• W2003013893 hasLocation W20030138933 @default.
• W2003013893 hasLocation W20030138934 @default.
• W2003013893 hasOpenAccess W2003013893 @default.
• W2003013893 hasPrimaryLocation W20030138931 @default.
• W2003013893 hasRelatedWork W2108035151 @default.
• W2003013893 hasRelatedWork W2116707205 @default.
• W2003013893 hasRelatedWork W2329206036 @default.
• W2003013893 hasRelatedWork W2409415991 @default.
• W2003013893 hasRelatedWork W2588687016 @default.
• W2003013893 hasRelatedWork W2902137755 @default.
• W2003013893 hasRelatedWork W2952212183 @default.
• W2003013893 hasRelatedWork W3173747928 @default.
• W2003013893 hasRelatedWork W3175751715 @default.
• W2003013893 hasRelatedWork W4280614914 @default.
• W2003013893 hasVolume "186" @default.
• W2003013893 isParatext "false" @default.

• next